Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions

2021; Elsevier BV; Volume: 39; Issue: 35 Linguagem: Inglês

10.1016/j.vaccine.2021.06.086

ISSN

1873-2518

Autores

Rachel S. Laufer, Amanda J. Driscoll, Ranju Baral, Andrea G. Buchwald, James D. Campbell, Flanon Coulibaly, Fatoumata Diallo, Moussa Doumbia, Alison P. Galvani, Fadima Cheick Haidara, Karen L. Kotloff, Adama Mamby Keita, Kathleen M. Neuzil, Evan Orenstein, Lauren A.V. Orenstein, Clint Pecenka, Samba O. Sow, Milagritos D. Tapia, Justin R. Ortiz, Meagan C. Fitzpatrick,

Tópico(s)

Emergency and Acute Care Studies

Resumo

Low- and middle-income countries have a high burden of respiratory syncytial virus lower respiratory tract infections. A monoclonal antibody administered monthly is licensed to prevent these infections, but it is cost-prohibitive for most low- and middle-income countries. Long-acting monoclonal antibodies and maternal vaccines against respiratory syncytial virus are under development.

Referência(s)